Low PARP-1 expression level is an indicator of poor prognosis in patients with stage II and III gastric canceropen access
- Authors
- Park, S.E.; Kim, H.S.; Jung, E.-J.; Suh, J.H.; Min, H.; Chi, K.-C.; Kim, J.W.; Park, J.-M.; Hwang, I.G.
- Issue Date
- Feb-2022
- Publisher
- Ivyspring International Publisher
- Keywords
- DNA damage response (DDR); Gastrectomy; Gastric cancer; Poly adenosine diphosphate-ribose polymerase 1 (PARP-1); Survival
- Citation
- Journal of Cancer, v.13, no.3, pp 869 - 876
- Pages
- 8
- Journal Title
- Journal of Cancer
- Volume
- 13
- Number
- 3
- Start Page
- 869
- End Page
- 876
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/54979
- DOI
- 10.7150/jca.65145
- ISSN
- 1837-9664
- Abstract
- Purpose: This study aimed to investigate the relationship between DNA damage response (DDR) related protein expression and clinical outcomes of patients with stage II and III gastric cancer undergoing gastrectomy. Materials and Methods: From January 2005 to December 2017, 217 gastrectomized patients with stage II and III gastric cancer were analyzed for disease-free and overall survival (DFS and OS, respectively) based on their DDR expression status. We performed the immunohistochemical assessment of MLH1, MSH2, at-rich interaction domain 1 (ARID1A), poly adenosine diphosphate-ribose polymerase 1 (PARP-1), breast cancer susceptibility gene 1 (BRCA1), and ataxia-telangiectasia mutated (ATM) using formalin-fixed paraffin-embedded (FFPE) samples. Results: Among the 217 patients studied, the most common DDR gene whose expression was suppressed was high PARP-1 (n = 120, 55.3%), followed by ATM (n = 62, 28.6%), ARID1A (n = 45, 20.7%), MLH1 (n = 33, 15.2%), BRCA1 (n = 25, 11.5%), and MSH2 (n = 9, 4.1%). The low-expression PARP-1 group exhibited a significantly shorter 5-year OS rate than the high-expression PARP-1 group (48.1% vs. 62.7%; HR 1.519, 95% CI = 1.011-2.283, P = 0.044). In the multivariate OS analysis, TNM stage (II vs. III) (HR = 5.172, P < 0.001), low PARP-1 expression (HR = 1.697, P = 0.013) and adjuvant chemotherapy (HR = 0.382, P < 0.001) were the only significant prognostic factors. Conclusions: Low PARP-1 expression level could be an indicator of poor prognosis in gastrectomized patients with stage II and III gastric cancer. © 2022 Ivyspring International Publisher. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/54979)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.